Vaginal hysterectomies are associated with superior patient outcomes and cost less than other methods of hysterectomy. So why is their rate of use declining?
Reports of women being criticized for “intense” workouts in late pregnancy are circulating the Web. Are these criticisms clinically warranted, or are the criticizers just bullies?
Physicians’ groups are urging ob/gyns to have difficult conversations with obese women about their weight. Here’s one example of how utter bluntness can be an effective tactic.
Discontinuation rates at 6 months among users of long-acting reversible contraceptive methods are low and not increased among adolescents and young women.
Patients with uterine fibroids have been advised to avoid a hysterectomy as treatment of the condition at all costs. Sound advice or mucky water?
A fertility pen, redesigned to incorporate updates and new features developed from patient and provider feedback, has been FDA approved and will be available December 2013.
The FDA has approved Duavee, the first medication to combine estrogen with bazedoxifene, for the treatment of hot flashes and the prevention of osteoporosis after menopause.
Accelerated approval of Perjeta (pertuzumab) was granted by the FDA as part of a complete treatment regimen for patients with early stage breast cancer before surgery.
To better balance the use of ultrasound and the time needed to ensure that an early pregnancy is not incorrectly declared nonviable, a group of experts have introduced new diagnostic thresholds.
The use of ice packs is an effective but nonstandard method of pain control after open abdominal surgery, and an experimental prolonged drug delivery system using nanotechnology is in the works.